États-Unis · Magazines éco · Axios Markets

Exclusive: OpenAI acquires biotech startup as AI race moves into drug development

Publié par Axios Markets · États-Unis il y a 11 h

OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development, the ChatGPT maker shared exclusively with Axios. Why it…

Lire l'article complet sur Axios Markets Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.axios.com)

Exclusive: OpenAI acquires biotech startup as AI race moves into drug development

À lire aussi

Why Your ChatGPT Traffic Dropped in October (And Why It Might Be a Reporting Trap)

SpaceX reported $4.4 billion net income as revenue rose 161% to $14.6 billion

SpaceX posts first operating profit as public company as AI revenue nearly triples to $7.6 billion—cruising past Starlink

Dow Gains 529 Points on 3M Data Center Deal: Stock Market Today

The Instincts That Got You Promoted Are Now Working Against You. Here’s How to Replace Them.

Voters might finally agree on something: They don’t want Matthew McConaughey in politics

Exclusive: OpenAI acquires biotech startup as AI race moves into drug development

Partager

À lire aussi

Why Your ChatGPT Traffic Dropped in October (And Why It Might Be a Reporting Trap)

SpaceX reported $4.4 billion net income as revenue rose 161% to $14.6 billion

SpaceX posts first operating profit as public company as AI revenue nearly triples to $7.6 billion—cruising past Starlink

Dow Gains 529 Points on 3M Data Center Deal: Stock Market Today

The Instincts That Got You Promoted Are Now Working Against You. Here’s How to Replace Them.

Voters might finally agree on something: They don’t want Matthew McConaughey in politics